las21 Antibody

What is LASP1 and what cellular functions does it regulate?

LASP1 (LIM and SH3 domain protein 1), also known as MLN50 or Metastatic lymph node gene 50 protein, is a cytoskeletal protein that plays a crucial role in regulating dynamic actin-based activities within cells. It participates in organizing the cytoskeleton and contributes to cell structure maintenance and motility. Additionally, agonist-dependent changes in LASP1 phosphorylation may serve to regulate actin-associated ion transport activities, particularly in F-actin-rich secretory epithelial cells . This role extends beyond parietal cells to other specialized secretory cell types, making LASP1 an important protein in studies of cellular architecture and transport mechanisms.

What applications are LASP1 antibodies suitable for?

LASP1 antibodies, such as the Rabbit Recombinant Monoclonal LASP1 antibody (ab156872), are validated for multiple experimental applications. They are primarily suitable for Western blotting (WB) and immunocytochemistry/immunofluorescence (ICC/IF) techniques when working with human samples . These antibodies enable researchers to detect and study LASP1 protein expression, localization, and post-translational modifications in various cell types and experimental conditions. The versatility of these applications makes LASP1 antibodies valuable tools in both basic research and more complex experimental designs investigating cytoskeletal dynamics and associated cellular processes.

How do I select the appropriate LASP1 antibody for my research?

When selecting a LASP1 antibody, consider several key factors: the species reactivity required for your samples, the specific applications you plan to use (such as WB or ICC/IF), the antibody's validated performance in peer-reviewed literature, and the clonality of the antibody. Recombinant monoclonal antibodies like ab156872 offer advantages in terms of batch-to-batch consistency and specificity . Review the antibody's validation data, including the predicted band size (30 kDa for LASP1) and performance across different cell lines. Additionally, examine citation records to gauge the antibody's reliability in published research. Many suppliers also offer performance guarantees for specific species and application combinations that have been thoroughly tested in-house.

How can I optimize Western blot protocols for LASP1 detection?

Optimizing Western blot protocols for LASP1 detection requires careful consideration of several parameters. Based on published research, LASP1 antibodies like ab156872 perform optimally at dilutions around 1/10000, significantly higher than typical antibody dilutions . For cell lysate preparation, successful detection has been demonstrated with 10 μg of total protein from various cell lines including SK-OV-3, A431, U87-MG, and 293T cells . The predicted molecular weight for LASP1 is approximately 30 kDa, so gel percentage and running conditions should be optimized accordingly.

For blocking and antibody incubation steps, conventional BSA or non-fat milk buffers typically yield good results, but optimization may be necessary depending on your specific experimental system. Consider overnight primary antibody incubation at 4°C to enhance signal quality while reducing background. Additionally, incorporate appropriate positive controls from cell lines known to express LASP1 and optimize the detection method based on your expected signal strength.

What are the best approaches for studying LASP1 in relation to cytoskeletal dynamics?

Studying LASP1 in relation to cytoskeletal dynamics requires a multi-methodological approach. Immunofluorescence techniques using LASP1 antibodies (at approximately 1/100 dilution for antibodies like ab156872) enable visualization of LASP1 distribution within the cell . Co-staining with actin filament markers provides valuable information about co-localization and potential functional interactions. Live-cell imaging combining fluorescently tagged LASP1 with cytoskeletal markers can reveal dynamic processes.

For functional studies, consider LASP1 knockdown or overexpression strategies followed by assessments of cytoskeletal organization, cell migration, and invasion capabilities. Phosphorylation-specific antibodies may help elucidate how post-translational modifications affect LASP1's interaction with the actin cytoskeleton. Additionally, proximity ligation assays can identify direct protein-protein interactions between LASP1 and potential binding partners in the cytoskeletal machinery. When designing these experiments, include appropriate controls and consider multiple cell types to account for cell-specific variations in LASP1 function.

How can I evaluate LASP1 phosphorylation states and their functional significance?

Evaluating LASP1 phosphorylation states requires targeted approaches similar to those used for other phosphoproteins. While specific phospho-LASP1 antibodies aren't mentioned in the search results, methodologies can be adapted from approaches used with other phospho-specific antibodies like p-ASK 1 Antibody (B-5) . Begin with phosphorylation-specific Western blotting using antibodies that recognize specific phosphorylated residues of LASP1.

For functional significance analysis, combine this with site-directed mutagenesis to create phospho-mimetic (e.g., Ser to Asp) or phospho-resistant (e.g., Ser to Ala) LASP1 variants. Express these in cell models and assess differences in localization, protein-protein interactions, and cellular functions. Mass spectrometry approaches can provide comprehensive mapping of all phosphorylation sites on LASP1 under various conditions. Additionally, kinase inhibitors or activators can help identify the signaling pathways regulating LASP1 phosphorylation. This multi-faceted approach will help establish connections between specific phosphorylation events and LASP1's roles in cytoskeletal organization and cellular functions.

What cell types are optimal for studying LASP1 function and expression?

Based on validated antibody testing, several cell lines have demonstrated reliable LASP1 expression and are suitable for functional studies. These include epidermoid carcinoma A431 cells, which show strong LASP1 expression in both Western blot and immunofluorescence applications . Additionally, SK-OV-3 (ovarian cancer), U87-MG (glioblastoma), and 293T (embryonic kidney) cell lines have been successfully used for LASP1 detection in Western blotting experiments .

When selecting cell models, consider the physiological relevance to your research question. For studying LASP1 in cancer contexts, use cell lines derived from relevant tumor types. For investigating fundamental cytoskeletal functions, established epithelial or fibroblast cell lines often provide consistent results. Primary cells from tissues known to express LASP1, particularly secretory epithelial cells, may offer more physiologically relevant insights into LASP1 function, though they typically present more technical challenges than immortalized cell lines.

How can I design co-immunoprecipitation experiments to identify LASP1 binding partners?

Co-immunoprecipitation (Co-IP) experiments to identify LASP1 binding partners should be designed with careful consideration of protein-protein interaction preservation. While specific Co-IP protocols for LASP1 aren't detailed in the search results, approaches can be adapted from general immunoprecipitation methodologies. Select mild lysis buffers (containing non-ionic detergents like NP-40 or Triton X-100) to maintain protein-protein interactions. For the immunoprecipitation step, LASP1 antibodies conjugated to agarose beads would be ideal.

After immunoprecipitation, analyze the co-precipitated proteins using techniques such as Western blotting for suspected binding partners or mass spectrometry for unbiased identification of the entire interactome. Include appropriate controls such as IgG control immunoprecipitations and input samples. To validate the specificity of identified interactions, perform reciprocal Co-IPs using antibodies against the putative binding partners. Additionally, consider cross-linking approaches for capturing transient interactions, and extend your studies to include conditions that might modulate these interactions, such as growth factor stimulation or cytoskeletal disruption.

What controls should be included in LASP1 immunofluorescence experiments?

Comprehensive controls are essential for reliable LASP1 immunofluorescence experiments. Based on standard practices for antibodies like ab156872 , include the following controls:

• Primary antibody controls: Include a condition without primary antibody but with secondary antibody to assess non-specific secondary antibody binding.

• Isotype controls: Use a non-specific antibody of the same isotype and concentration as your LASP1 antibody to identify potential non-specific binding.

• Antigen competition controls: Pre-incubate the LASP1 antibody with purified LASP1 protein or a specific blocking peptide before staining to confirm binding specificity.

• Knockdown/knockout controls: Include cells where LASP1 has been knocked down or knocked out to demonstrate antibody specificity.

• Positive controls: Include cells known to express LASP1 at high levels, such as A431 cells.

• Co-localization controls: If studying LASP1 in relation to cytoskeletal structures, include co-staining with established markers of those structures.

Additionally, maintain consistent imaging parameters across all samples and controls, and incorporate quantitative analysis methods to objectively assess staining patterns and intensity differences between experimental conditions.

How can I address non-specific banding in Western blots with LASP1 antibodies?

Non-specific banding in LASP1 Western blots can be addressed through several methodological adjustments. First, optimize antibody dilution—for antibodies like ab156872, high dilutions (1/10000) have been validated to provide specific detection . Consider increasing the blocking time or concentration of blocking agent to reduce non-specific binding. For LASP1, which has a predicted band size of 30 kDa, adjust gel percentage to optimize separation in this molecular weight range.

Additional strategies include optimizing transfer conditions (time, voltage, buffer composition) to ensure efficient transfer of proteins in the LASP1 molecular weight range. Washing steps should be thorough but gentle to maintain specific binding while reducing background. If persistent non-specific bands occur, consider using alternative lysis buffers that may better preserve protein in its native form or adding phosphatase inhibitors if studying phosphorylated forms of LASP1. Finally, comparing results from multiple LASP1 antibodies targeting different epitopes can help confirm which bands represent genuine LASP1 detection.

What methodological adaptations are needed when studying LASP1 in different tissue types?

When studying LASP1 across diverse tissue types, several methodological adaptations are necessary. For tissue homogenization and protein extraction, optimize lysis buffer composition based on the tissue's characteristics—tougher tissues may require mechanical disruption methods or stronger lysis buffers, while preserving protein integrity remains essential. Extraction protocols should be adjusted to address tissue-specific challenges such as high lipid content or abundant extracellular matrix.

For immunohistochemical detection, optimize antigen retrieval methods based on the fixation protocol used. Antibody concentrations may need adjustment for different tissues—while 1/100 dilution works well for cultured cells like A431 , tissue sections often require different concentrations due to fixation effects and tissue-specific background. Counterstaining strategies should be selected to provide appropriate tissue architecture context while allowing clear visualization of LASP1 staining. Additionally, incorporate tissue-specific positive and negative controls, and when possible, validate findings using complementary techniques such as in situ hybridization for LASP1 mRNA or multiple antibodies targeting different LASP1 epitopes.

How do antibody cross-reactivity issues affect LASP1 research, and how can they be mitigated?

Antibody cross-reactivity can significantly impact LASP1 research findings. LASP1 shares structural domains (LIM and SH3) with other proteins, creating potential for cross-reactivity. To mitigate these issues, employ a multi-layered validation strategy. First, select antibodies with demonstrated specificity, like recombinant monoclonal antibodies which typically offer higher specificity than polyclonal alternatives . Verify antibody specificity using LASP1 knockout or knockdown models where the specific band or signal should be absent or significantly reduced.

Perform epitope mapping to understand which region of LASP1 the antibody recognizes, which helps predict potential cross-reactivity. Include competition assays with purified LASP1 protein to confirm binding specificity. When possible, use multiple antibodies targeting different LASP1 epitopes and compare results. For complex or novel tissue samples, validate findings with orthogonal techniques such as mass spectrometry or mRNA detection. Additionally, thoroughly review the literature for known cross-reactivity issues with specific LASP1 antibodies, as this information can guide antibody selection and experimental design to minimize misinterpretation of results.

How can LASP1 antibody research inform therapeutic antibody development strategies?

LASP1 antibody research provides valuable insights applicable to therapeutic antibody development. The strategies used to develop highly specific antibodies like the rabbit recombinant monoclonal LASP1 antibody inform approaches for therapeutic antibody engineering. While therapeutic applications differ from research reagents, the principles of epitope selection, antibody engineering, and specificity validation remain relevant.

Recent breakthroughs in broadly neutralizing antibodies, such as SC27 for COVID-19 , demonstrate how detailed molecular characterization of antibody-target interactions can lead to therapeutically valuable antibodies. The SC27 antibody's ability to recognize and neutralize multiple SARS-CoV-2 variants illustrates the importance of targeting conserved epitopes —a principle that could be applied when developing therapeutics against LASP1 or related targets. Additionally, technologies used for antibody discovery and characterization, such as the Ig-Seq approach mentioned for isolating SC27 , represent powerful platforms that can accelerate the development of novel therapeutic antibodies across various disease contexts.

What are the challenges in developing phospho-specific antibodies for LASP1 research?

Developing phospho-specific antibodies for LASP1 presents several challenges similar to those encountered with other phospho-specific antibodies like p-ASK 1 antibody . The first major challenge is epitope design—creating an immunogen that precisely represents the phosphorylated form of LASP1 at specific residues while maintaining sufficient immunogenicity. This requires detailed knowledge of LASP1's phosphorylation sites and their surrounding sequences.

Antibody validation presents another significant challenge, requiring demonstration of phospho-specificity through multiple approaches. These typically include showing differential reactivity between phosphorylated and dephosphorylated LASP1 (via phosphatase treatment), phospho-mimetic and phospho-resistant mutants, and cells treated with kinase activators versus inhibitors. Background reactivity can be particularly problematic with phospho-specific antibodies, necessitating extensive negative controls. Additionally, the transient nature of phosphorylation events requires careful sample preparation with phosphatase inhibitors and optimization of fixation protocols for immunocytochemistry applications to preserve phosphorylation status during processing.

How might recent advances in antibody technology enhance LASP1 research?

Recent advances in antibody technology present several opportunities to enhance LASP1 research. The development of technologies like Ig-Seq, which was used to characterize the broadly neutralizing SC27 antibody , could be applied to identify novel LASP1-specific antibodies with improved properties. These high-throughput screening approaches enable more efficient identification of antibodies with specific characteristics, such as phospho-state specificity or improved affinity.

Recombinant antibody technologies, exemplified by the rabbit recombinant monoclonal LASP1 antibody , offer advantages in reproducibility and can be further engineered for specific research applications. Additionally, advances in antibody conjugation technologies provide opportunities for developing multi-functional LASP1 research tools. For instance, site-specific conjugation methods could enable the creation of LASP1 antibodies directly linked to fluorophores, enzymes, or other functional moieties with minimal impact on antigen binding.

Furthermore, the development of smaller antibody formats such as nanobodies or single-chain variable fragments could provide research tools with enhanced tissue penetration for in vivo imaging or improved access to structurally constrained epitopes within the LASP1 protein.